Valuation: CEL-SCI Corporation

Market Cap 2.99Cr 2.63Cr 2.49Cr 2.26Cr 4.24Cr 287.03Cr 4.26Cr 30Cr 11Cr 146.46Cr 11Cr 11Cr 470.66Cr P/E 2026 *
-0.55x
P/E 2027 * -0.27x
Enterprise Value 2.43Cr 2.14Cr 2.02Cr 1.84Cr 3.45Cr 233.71Cr 3.47Cr 24Cr 9.36Cr 119.26Cr 9.14Cr 8.94Cr 383.23Cr EV / Sales 2026 *
-
EV / Sales 2027 * 4.11x
Free-Float
96.32%
Yield 2026 *
-
Yield 2027 * -
1 day+1.80%
1 week+1.80%
Current month+4.94%
1 month+8.97%
3 months+53.15%
6 months-46.88%
Current year-67.68%
1 week 1.66
Extreme 1.665
1.76
1 month 1.46
Extreme 1.46
1.76
Current year 0.89
Extreme 0.89
6.75
1 year 0.89
Extreme 0.89
10.83
3 years 0.89
Extreme 0.89
96.91
5 years 0.89
Extreme 0.89
384.64
10 years 0.89
Extreme 0.89
1,227.42
Manager TitleAgeSince
Chief Executive Officer 67 01/01/1995
Director of Finance/CFO 75 13/11/2024
Chief Tech/Sci/R&D Officer - 01/05/2024
Director TitleAgeSince
Director/Board Member 67 01/01/1995
Director/Board Member 73 22/06/2015
Chairman 69 08/07/2024
Date Insider Type Main position Quantity % Market Cap. Importance
25/08/26 Buy

Chief Executive Officer

1,00,000 0.5722%
14/08/26 Free

Chief Financial Officer

2,25,000 1.2874%
14/08/26 Free

Director

1,10,000 0.6294%
Change 5-day change 1-year change 3-year change Capi.($)
+1.80%+1.80%-81.01%-95.32% 2.94Cr
-0.37%-3.67%+57.21%+87.75% 7.23TCr
-0.07%-2.70%+37.74%+86.90% 6.02TCr
-0.28%+1.42%+34.85%+16.98% 2.77TCr
-0.14%-2.75%-14.13%+356.79% 2.57TCr
+0.57%+1.10%+1.02%-2.89% 2.47TCr
+1.10%+1.86%+25.07%-7.59% 2.07TCr
-1.70%+0.43%+150.24%+323.16% 1.51TCr
+0.36%+2.01%+49.51%+160.70% 1.44TCr
+4.53%-2.86%-3.91%+521.67% 1.42TCr
Average +0.62%-0.04%+25.66%+144.81% 2.75TCr
Weighted average by Cap. +0.17%-1.08%+38.06%+129.38%

Financials

2026 *2027 *
Net sales - 59.72L 52.52L 49.67L 45.05L 84.6L 57Cr 85.1L 5.95Cr 2.3Cr 29Cr 2.24Cr 2.19Cr 94Cr
Net income -2.51Cr -2.21Cr -2.09Cr -1.89Cr -3.55Cr -240.79Cr -3.57Cr -25Cr -9.65Cr -122.87Cr -9.42Cr -9.21Cr -394.83Cr -2.95Cr -2.6Cr -2.45Cr -2.23Cr -4.18Cr -283.31Cr -4.21Cr -29Cr -11Cr -144.57Cr -11Cr -11Cr -464.56Cr
Net Debt -55.54L -48.85L -46.19L -41.9L -78.68L -53Cr -79.14L -5.53Cr -2.14Cr -27Cr -2.09Cr -2.04Cr -87Cr -53.39L -46.96L -44.4L -40.27L -75.64L -51Cr -76.08L -5.32Cr -2.05Cr -26Cr -2Cr -1.96Cr -84Cr
Logo CEL-SCI Corporation
CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).
Employees
44
Date Price Change Volume
28/26/28 $1.700 +1.80% 1,26,182
25/26/25 $1.670 -2.91% 36,410
24/26/24 $1.720 +2.38% 56,130
23/26/23 $1.680 -1.18% 1,71,391
22/26/22 $1.700 +1.80% 1,33,848
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.700USD
Average target price
12.50USD
Spread / Average Target
+635.29%

Annual profits - Rate of surprise